These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 11892894

  • 1. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
    Dorai-John T, Thomson CJ, Amyes SG.
    J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
    [Abstract] [Full Text] [Related]

  • 2. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
    Lopez H, Vilches V, Scarano S, Stepanik D, Smayevsky J, Lemme L, Cardeñosa O, Ambler J, Sucari A.
    Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
    [Abstract] [Full Text] [Related]

  • 3. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.
    Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF.
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
    Loza E, Morosini M, Negri MC, Almaraz F, Cantón R, Baquero F.
    Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023
    [Abstract] [Full Text] [Related]

  • 6. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
    Blondeau JM, Vaughan D, Laskowski R, Borsos S, Canadian Antimicrobial Study Group.
    Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Brueggemann AB, Kugler KC, Doern GV.
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of fluoroquinolones against common respiratory pathogens.
    Aydemir S, Tunger A, Cilli F.
    West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
    [Abstract] [Full Text] [Related]

  • 10. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
    Biedenbach DJ, Barrett MS, Croco MA, Jones RN.
    Diagn Microbiol Infect Dis; 1998 Sep; 32(1):45-50. PubMed ID: 9791757
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I, Robbins M, Viljoen L, Brown DF.
    J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
    [Abstract] [Full Text] [Related]

  • 12. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T, Domingo D, Prieto N, Sánchez S, López-Brea M.
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [Abstract] [Full Text] [Related]

  • 13. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E, Dalhoff A, Korfmann G.
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [Abstract] [Full Text] [Related]

  • 14. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
    Biedenbach DJ, Jones RN, Pfaller MA, Sentry Participants Group (Americas and Europe).
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
    [Abstract] [Full Text] [Related]

  • 15. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
    Esposito S, Noviello S, Ianniello F.
    Chemotherapy; 2000 Apr; 46(5):309-14. PubMed ID: 10965095
    [Abstract] [Full Text] [Related]

  • 16. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.
    Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF.
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2645-52. PubMed ID: 10991838
    [Abstract] [Full Text] [Related]

  • 17. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.
    Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF.
    Clin Microbiol Infect; 2003 Jul; 9(7):590-9. PubMed ID: 12925097
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).
    Deshpande LM, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):139-42. PubMed ID: 10863108
    [Abstract] [Full Text] [Related]

  • 20. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.